BBOT · CIK 0001869105
What BridgeBio Oncology Therapeutics, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for BBOT. More may follow as additional filings are processed.
In its own words
What could break it.
Regulatory & policy
- US tariffs on API/raw materials & Section 232 pharma probemedium
Although pharmaceutical end-products are currently excluded from some tariffs, US import tariffs raise R&D costs for APIs, raw materials and lab equipment, and a Section 232 investigation into pharma/API imports is underway.
“While pharmaceutical end-products are currently excluded from certain tariffs, current or future tariffs will result in increased research and development expenses, including with respect to increased costs associated with active pharmaceutical ingredients (APIs), raw materials, laboratory equipment and research materials and components. In addition, the U.S. Department of Commerce is conducting a Section 232 investigation to assess the national security implications of pharmaceutical and API imports.”
Sole-source dependency
- sole-source suppliers incl. China-based (API/drug product); BIOSECURE riskmedium
Relies on sole-source third-party suppliers — including for key APIs, drug product and starting materials — some of which are China-based companies named in BIOSECURE-style 'of concern' legislation, creating supply and contracting risk.
“Some of BBOT's sole source suppliers are companies in China, including some named in these bills, and it is possible some of BBOT's contractual counterparties could be impacted by the legislation described above.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch